FDA Green Lights Promising New Continuous Glucose Monitoring System

FDA Green Lights Promising New Continuous Glucose Monitoring SystemOn Monday, DexCom, Inc. — a provider of glucose monitoring solutions for patients with diabetes — announced that it has received U.S. Food and Drug Administration’s approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share.

According to a statement provided to mHealthWatch, the Dexcom Share receiver uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient’s receiver and an app on the patient’s smartphone to transmit glucose information to apps on the mobile devices of up to five designated recipients.

This can happen, the company says, without the need for a dedicated docking cradle.

Those remotely monitoring a patient’s glucose information can receive alert notifications from almost anywhere, initially via their iPhone or iPod touch (and in the future on Android devices).

“The Dexcom Share receiver represents a significant step forward for our company and our mobile strategy, but more importantly, it will provide a huge improvement for people managing their diabetes and for those parents and caregivers who help them each and every day,” says Kevin Sayer, CEO of Dexcom. “The FDA understands the importance of this type of innovation and the need to regulate it appropriately, and we could not be more pleased with the speed at which they reviewed and approved this important innovation.”

This post was written by:

- who has written 567 posts on mHealthWatch.


Contact the author

Advert